| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5050f8a78737ea730347d5e3d039fd0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-14 |
| filingDate |
2019-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55afe7550a741eb0e5ba8d8b290fd9df |
| publicationDate |
2020-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020002740-A1 |
| titleOfInvention |
Dalbavancin in the treatment of bacterial respiratory tract infections in children and pediatric patients |
| abstract |
The present invention relates to the use of a lipoglycopeptide antibiotic, dalbavancin, for the treatment of respiratory tract diseases, preferably pneumonia, in individuals aged under 18 years. |
| priorityDate |
2018-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |